Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year.

908 Devices Enhances MX908 Usability and Adds New Drug Targets

BURLINGTON, Mass.--(BUSINESS WIRE)-- #chemicalID--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 mass spectrometry device for trace chemical identification. These enhancements include an updated mission mode for hazardous vapor sampling and the addition of five priority drug targets, providing first responders with intelligence at the point of need for an informed, confident response. The MX908 mission mode.

908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2025. Preliminary unaudited revenue for the fourth quarter of 2025 is approximately $17.2 million, compared to $14.3 million in the fourth quarter of 2024, reflecting reported gro.

908 Devices Reports Third Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended September 30, 2025. “We are pleased with our year-to-date progress as we continue to build a more predictable and profitable business and bring our 908 Devices 2.0 vision to life,” said Kevin J. Knopp, CEO and Co-founder. “Revenue for the f.